<DOC>
	<DOCNO>NCT02295449</DOCNO>
	<brief_summary>Background : Bracco release VueBoxTM-Prostate software , aim distinguish prostate cancer prostate benign peripheral zone ( PZ ) contrast-enhanced ultrasound ( CEUS ) use SonoVue® contrast agent . The software analyse ascend phase enhancement ( wash-in ) calculate mode dispersion ( sigma ) wash-in rate give region interest . The diagnosis cancer base combination two parameter . The main objective study evaluate diagnostic value VueBoxTM-Prostate software distinguish prostate cancer normal PZ contrast-enhanced ultrasound ( CEUS ) . The secondary objective evaluate diagnostic value wash-out rate , time peak , transit time area enhancement curve ( parameter use VueBoxTM-Prostate software ) distinguish prostate cancer prostate benign peripheral zone contrast-enhanced ultrasound ( CEUS ) . The study enroll patient refer prostate biopsy . The US transrectal probe insert local anesthesia perform per institution 's standard care protocol . Then , biopsy operator choose axial plane likely contain cancer ( e.g . base MRI Digital rectal examination result ) . Half vial ( 2.4 ml ) SonoVue® inject ultrasound enhancement plane record 2 minute biopsy gun already place . Then , biopsy take recording still , possible calculate quantitative enhancement parameter exact location biopsy . Then , operator choose plane likely contain cancer opposite prostate lobe process repeat injection second half vial . The rest biopsy perform per institution 's standard care protocol . The two recording send Bracco 's Research center Geneva order : - Predict biopsy result ( cancer vs benign ) base VueBoxTM-Prostate software result - Calculate wash-out rate , time peak , transit time area enhancement curve biopsy location . The two biopsy sample perform injection SonoVue® ( rest biopsy sample ) process analysed institution 's department Pathology result blind Bracco 's Research center . The correlation biopsy result , VueBoxTM-Prostate software result wash-out rate , time peak , transit time area enhancement curve perform study investigator . In total , 130 patient include ( hypothesis 20 % malignant biopsy core area ROC curve 0.85 VueBoxTM-Prostate software ) .</brief_summary>
	<brief_title>Quantitative Prostate Cancer Contrast-enhanced Ultrasound</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patient refer prostate biopsy Informed consent sign Patient affiliate French Health Insurance History allergy SonoVue® History myocardial infarction angor pectoris History severe pulmonary arterial hypertension ( &gt; 90 mm Hg ) History previous treatment prostate cancer ( radiation therapy , brachytherapy , highintensity focus ultrasound , etc… ) History hormone therapy prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Contrast-enhanced ultrasound</keyword>
</DOC>